Please note: This activity and competition is now closed.
Become part of our reviewer team, help us develop educational resources on this major development in T2D management
We’re reaching out to a very select group of GPs to get your feedback on this resource. You will be providing important input for our education team to better understand the relevance of the topic and the suitability of the resource for wider consumption by your colleagues in the GP community. By watching this lecture and filling out the short post-lecture questionnaire you will receive:
- 30 mins EA CPD
- 30 mins RP CPD
- A $50 Westfield voucher* (for the first 20 questionnaire completions) after which, those that complete before the deadline, will go into the prize draw to win one of five $100 Westfield gift vouchers*
Limited spots available on the reviewing team! We need a maximum of 200 responses to participate in this questionnaire.
This activity will close once we have reached the required number of participants, or by Monday 17 February 2025 at 5:00PM AEDT.
Topic Summary
Chronic kidney disease in those with T2 Diabetes has been, until now, understood to be an inevitable, progressive disease ending with dialysis and/or transplant. Recently, clinical trials have shown that Finerenone, a mineralocorticoid antagonist, has been show to significantly delay this progressive deterioration with obvious and significant benefits both in terms of individual patient outcomes as well as, in a broader sense, the health economics of these major health issues. GPs will play a key role in the implementation of this important development in T2D management. In this lecture, Dr Bobby Chan describes the theory, evidence and practical advice on how you, the GP, can begin using this drug in suitable patients.
Expert Speaker
- Dr Bobby Chan | Endocrinologist, Diabetes Specialist and Weight Loss Physician
